[Articles] Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2 –17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study

TDV was well tolerated and immunogenic against all four dengue serotypes, irrespective of baseline dengue serostatus. These data provide proof of concept for TDV and support the ongoing phase 3 efficacy assessment of two doses 3 months apart.

Source: The Lancet Infectious Diseases - November 6, 2017 Category: Infectious Diseases Authors: Xavier S áez-Llorens, Vianney Tricou, Delia Yu, Luis Rivera, José Jimeno, Ana Cecilia Villarreal, Epiphany Dato, Sonia Mazara, Maria Vargas, Manja Brose, Martina Rauscher, Suely Tuboi, Astrid Borkowski, Derek Wallace Tags: Articles Source Type: research